225 related articles for article (PubMed ID: 37902966)
1. Cardiovascular outcomes by time-varying New York Heart Association class among patients with obstructive hypertrophic cardiomyopathy: a retrospective cohort study.
Wang Y; Gao W; Han X; Jiang J; Sandler B; Li X; Zema C
J Med Econ; 2023; 26(1):1495-1506. PubMed ID: 37902966
[TBL] [Abstract][Full Text] [Related]
2. Association of Race With Disease Expression and Clinical Outcomes Among Patients With Hypertrophic Cardiomyopathy.
Eberly LA; Day SM; Ashley EA; Jacoby DL; Jefferies JL; Colan SD; Rossano JW; Semsarian C; Pereira AC; Olivotto I; Ingles J; Seidman CE; Channaoui N; Cirino AL; Han L; Ho CY; Lakdawala NK
JAMA Cardiol; 2020 Jan; 5(1):83-91. PubMed ID: 31799990
[TBL] [Abstract][Full Text] [Related]
3. Association of Obesity With Adverse Long-term Outcomes in Hypertrophic Cardiomyopathy.
Fumagalli C; Maurizi N; Day SM; Ashley EA; Michels M; Colan SD; Jacoby D; Marchionni N; Vincent-Tompkins J; Ho CY; Olivotto I;
JAMA Cardiol; 2020 Jan; 5(1):65-72. PubMed ID: 31693057
[TBL] [Abstract][Full Text] [Related]
4. Incidence, Clinical Characteristics, and Long-term Outcome of the Dilated Phase of Hypertrophic Cardiomyopathy.
Aizawa Y; Tanimoto Y; Hirata Y; Fujisawa T; Fukuoka R; Nakajima K; Katsumata Y; Nishiyama T; Kimura T; Yuasa S; Kohno T; Kohsaka S; Murata M; Maekawa Y; Furukawa Y; Takatsuki S; Fukuda K
Keio J Med; 2019 Dec; 68(4):87-94. PubMed ID: 30606897
[TBL] [Abstract][Full Text] [Related]
5. Projecting the Long-term Clinical Value of Mavacamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy in the United States: An Assessment of Net Health Benefit.
Desai N; Xie J; Wang Y; Sutton MB; Whang J; Fine JT; Garrison LP
Clin Ther; 2022 Jan; 44(1):52-66.e2. PubMed ID: 34911641
[TBL] [Abstract][Full Text] [Related]
6. Identifying unmet clinical need in hypertrophic cardiomyopathy using national electronic health records.
Pujades-Rodriguez M; Guttmann OP; Gonzalez-Izquierdo A; Duyx B; O'Mahony C; Elliott P; Hemingway H
PLoS One; 2018; 13(1):e0191214. PubMed ID: 29324812
[TBL] [Abstract][Full Text] [Related]
7. Clinical Outcomes in Patients With Nonobstructive, Labile, and Obstructive Hypertrophic Cardiomyopathy.
Lu DY; Pozios I; Haileselassie B; Ventoulis I; Liu H; Sorensen LL; Canepa M; Phillip S; Abraham MR; Abraham TP
J Am Heart Assoc; 2018 Feb; 7(5):. PubMed ID: 29478967
[TBL] [Abstract][Full Text] [Related]
8. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial.
Olivotto I; Oreziak A; Barriales-Villa R; Abraham TP; Masri A; Garcia-Pavia P; Saberi S; Lakdawala NK; Wheeler MT; Owens A; Kubanek M; Wojakowski W; Jensen MK; Gimeno-Blanes J; Afshar K; Myers J; Hegde SM; Solomon SD; Sehnert AJ; Zhang D; Li W; Bhattacharya M; Edelberg JM; Waldman CB; Lester SJ; Wang A; Ho CY; Jacoby D;
Lancet; 2020 Sep; 396(10253):759-769. PubMed ID: 32871100
[TBL] [Abstract][Full Text] [Related]
9. Pulmonary hypertension is associated with worse survival in hypertrophic cardiomyopathy.
Ong KC; Geske JB; Hebl VB; Nishimura RA; Schaff HV; Ackerman MJ; Klarich KW; Siontis KC; Coutinho T; Dearani JA; Ommen SR; Gersh BJ
Eur Heart J Cardiovasc Imaging; 2016 Jun; 17(6):604-10. PubMed ID: 26922089
[TBL] [Abstract][Full Text] [Related]
10. Impact of pregnancy on the natural history of women with hypertrophic cardiomyopathy.
Fumagalli C; Zocchi C; Cappelli F; Celata A; Tassetti L; Sasso L; Zampieri M; Argirò A; Marchi A; Targetti M; Berteotti M; Maurizi N; Mori F; Livi P; Baldini K; Tomberli A; Girolami F; Favilli S; Mecacci F; Olivotto I
Eur J Prev Cardiol; 2024 Jan; 31(1):3-10. PubMed ID: 37531614
[TBL] [Abstract][Full Text] [Related]
11. Impact of gender on heart failure presentation in non-obstructive hypertrophic cardiomyopathy.
Jang JH; Shin SH; Beak YS; Ko KY; Kwon SW; Park SD; Woo SI; Kim DH; Kwan J
Heart Vessels; 2020 Feb; 35(2):214-222. PubMed ID: 31482215
[TBL] [Abstract][Full Text] [Related]
12. Stroke-Heart Syndrome: Incidence and Clinical Outcomes of Cardiac Complications Following Stroke.
Buckley BJR; Harrison SL; Hill A; Underhill P; Lane DA; Lip GYH
Stroke; 2022 May; 53(5):1759-1763. PubMed ID: 35354300
[TBL] [Abstract][Full Text] [Related]
13. Biventricular pacing (cardiac resynchronization therapy): an evidence-based analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2005; 5(13):1-60. PubMed ID: 23074464
[TBL] [Abstract][Full Text] [Related]
14. Stroke risk in hypertrophic cardiomyopathy patients with atrial fibrillation: a nationwide database study.
Hsu JC; Huang YT; Lin LY
Aging (Albany NY); 2020 Nov; 12(23):24219-24227. PubMed ID: 33226371
[TBL] [Abstract][Full Text] [Related]
15. Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy: Insights from the Sarcomeric Human Cardiomyopathy Registry (SHaRe).
Ho CY; Day SM; Ashley EA; Michels M; Pereira AC; Jacoby D; Cirino AL; Fox JC; Lakdawala NK; Ware JS; Caleshu CA; Helms AS; Colan SD; Girolami F; Cecchi F; Seidman CE; Sajeev G; Signorovitch J; Green EM; Olivotto I
Circulation; 2018 Oct; 138(14):1387-1398. PubMed ID: 30297972
[TBL] [Abstract][Full Text] [Related]
16. Clinical features of the dilated phase of hypertrophic cardiomyopathy in comparison with those of dilated cardiomyopathy.
Hamada T; Kubo T; Kitaoka H; Hirota T; Hoshikawa E; Hayato K; Shimizu Y; Okawa M; Yamasaki N; Matsumura Y; Yabe T; Takata J; Doi YL
Clin Cardiol; 2010 Jul; 33(7):E24-8. PubMed ID: 20641106
[TBL] [Abstract][Full Text] [Related]
17. Enhanced External Counterpulsation (EECP): An Evidence-Based Analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2006; 6(5):1-70. PubMed ID: 23074496
[TBL] [Abstract][Full Text] [Related]
18. Assessing health-related quality-of-life in patients with symptomatic obstructive hypertrophic cardiomyopathy: EQ-5D-based utilities in the EXPLORER-HCM trial.
Xie J; Wang Y; Xu Y; Fine JT; Lam J; Garrison LP
J Med Econ; 2022; 25(1):51-58. PubMed ID: 34907813
[TBL] [Abstract][Full Text] [Related]
19. Ischemic Stroke in Patients With Hypertrophic Cardiomyopathy According to Presence or Absence of Atrial Fibrillation.
Fauchier L; Bisson A; Bodin A; Herbert J; Spiesser P; Pierre B; Clementy N; Bernard A; Babuty D; Lip GYH
Stroke; 2022 Feb; 53(2):497-504. PubMed ID: 34601900
[TBL] [Abstract][Full Text] [Related]
20. Tissue Doppler imaging and prognosis in asymptomatic or mildly symptomatic patients with hypertrophic cardiomyopathy.
Kitaoka H; Kubo T; Hayashi K; Yamasaki N; Matsumura Y; Furuno T; Doi YL
Eur Heart J Cardiovasc Imaging; 2013 Jun; 14(6):544-9. PubMed ID: 23060455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
